Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 17% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-08-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients mustmyocardialableeffectiveunstable
  Phrases that lowered it: adultaminotransferasedisorderhepatic impairmentor suspected
• Sponsor's past termination rate: 27.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Primary purpose: prevention (lowers risk) · Design
• Drug's FAERS reports with a death: 28.2% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 648 (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission NCT02302846 · started 2015 · scored riskier than 80% of active trials terminated
• Empirical Versus Preemptive Antifungal Therapy NCT01288378 · started 2012 · scored riskier than 73% of active trials completed
• Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED) NCT00811928 · started 2008 · scored riskier than 42% of active trials completed
• MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age NCT02582359 · started 2016 · scored riskier than 75% of active trials completed
• A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission NCT03850535 · started 2019 · scored riskier than 62% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.